RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site
Oncogenic RAS mutants remain difficult to target with small molecules. Here, the authors show that RAS-binding Affimer proteins inhibit RAS signaling while binding diverse regions on the RAS surface, suggesting the potential to use Affimers as tools to identify new binding pockets and pharmacophores...
Guardado en:
Autores principales: | Katarzyna Z. Haza, Heather L. Martin, Ajinkya Rao, Amy L. Turner, Sophie E. Saunders, Britta Petersen, Christian Tiede, Kevin Tipping, Anna A. Tang, Modupe Ajayi, Thomas Taylor, Maia Harvey, Keri M. Fishwick, Thomas L. Adams, Thembaninkosi G. Gaule, Chi H. Trinh, Matthew Johnson, Alexander L. Breeze, Thomas A. Edwards, Michael J. McPherson, Darren C. Tomlinson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9fb0e318fb534431a1e30f0ac4d27ca1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
- Demokratizat?sii?a
-
Farmat?sii?a
Publicado: (1967) -
Boletin Oficial SII
Publicado: (2008) -
Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma
por: Mark Manzano, et al.
Publicado: (2018) -
KRAS mutation: from undruggable to druggable in cancer
por: Lamei Huang, et al.
Publicado: (2021)